HIV/AIDS
Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe
Published in AIDS Weekly and Law, March 8th, 2007
If approved by the regulatory agencies, maraviroc will be the first in a new class of HIV/AIDS treatments called CCR5 antagonists that work by blocking viral entry. Rather than fighting HIV inside white blood cells, CCR5 antagonists prevent the virus produced by infected cells from entering uninfected cells by blocking its predominant entry route, the CCR5 co- receptor.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly and Law
Source: AIDS Weekly and Law (2007-03-08)
More Articles from AIDS Weekly and Law
- HIV/AIDS
AIDS Healthcare Foundation to Petition FDA to Stop Pfizer Pursuit of OTC Approval for Viagra - Financials
Polydex Pharmaceuticals Issues Interim Report on Business Operations - Gene Therapy
RNAi Shows Promise in Gene Therapy, Stanford Researcher Says - HIV/AIDS
Africa's first large-scale HIV vaccine study launches - HIV/AIDS
Amarillo Biosciences Announces Open Enrollment in its Phase 2 Study of Orally Administered Interferon Alpha in the Treatment of Oral Warts in HIV-Positive Patients - HIV/AIDS
Anti-HIV Medication PREZISTA (Darunavir) Receives Conditional Marketing Authorisation In The European Union - More from this issue of AIDS Weekly and Law
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
